323 related articles for article (PubMed ID: 15611092)
1. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins.
Taniguchi S; Suzuki N; Masuda M; Hisanaga S; Iwatsubo T; Goedert M; Hasegawa M
J Biol Chem; 2005 Mar; 280(9):7614-23. PubMed ID: 15611092
[TBL] [Abstract][Full Text] [Related]
2. Biochemistry and molecular biology of tauopathies.
Hasegawa M
Neuropathology; 2006 Oct; 26(5):484-90. PubMed ID: 17080729
[TBL] [Abstract][Full Text] [Related]
3. Small molecule inhibitors of alpha-synuclein filament assembly.
Masuda M; Suzuki N; Taniguchi S; Oikawa T; Nonaka T; Iwatsubo T; Hisanaga S; Goedert M; Hasegawa M
Biochemistry; 2006 May; 45(19):6085-94. PubMed ID: 16681381
[TBL] [Abstract][Full Text] [Related]
4. Different inhibitory response of cyanidin and methylene blue for filament formation of tau microtubule-binding domain.
Hattori M; Sugino E; Minoura K; In Y; Sumida M; Taniguchi T; Tomoo K; Ishida T
Biochem Biophys Res Commun; 2008 Sep; 374(1):158-63. PubMed ID: 18619417
[TBL] [Abstract][Full Text] [Related]
5. Taxol-stabilized microtubules promote the formation of filaments from unmodified full-length Tau in vitro.
Duan AR; Goodson HV
Mol Biol Cell; 2012 Dec; 23(24):4796-806. PubMed ID: 23087208
[TBL] [Abstract][Full Text] [Related]
6. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation.
Crowe A; Ballatore C; Hyde E; Trojanowski JQ; Lee VM
Biochem Biophys Res Commun; 2007 Jun; 358(1):1-6. PubMed ID: 17482143
[TBL] [Abstract][Full Text] [Related]
7. Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease.
Goedert M; Spillantini MG
Biochim Biophys Acta; 2000 Jul; 1502(1):110-21. PubMed ID: 10899436
[TBL] [Abstract][Full Text] [Related]
8. Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer's Disease.
Soeda Y; Saito M; Maeda S; Ishida K; Nakamura A; Kojima S; Takashima A
J Alzheimers Dis; 2019; 68(4):1677-1686. PubMed ID: 30909223
[TBL] [Abstract][Full Text] [Related]
9. Cysteine-Independent Inhibition of Alzheimer's Disease-like Paired Helical Filament Assembly by Leuco-Methylthioninium (LMT).
Al-Hilaly YK; Pollack SJ; Rickard JE; Simpson M; Raulin AC; Baddeley T; Schellenberger P; Storey JMD; Harrington CR; Wischik CM; Serpell LC
J Mol Biol; 2018 Oct; 430(21):4119-4131. PubMed ID: 30121297
[TBL] [Abstract][Full Text] [Related]
10. Aggregation Kinetics and Filament Structure of a Tau Fragment Are Influenced by the Sulfation Pattern of the Cofactor Heparin.
Townsend D; Fullwood NJ; Yates EA; Middleton DA
Biochemistry; 2020 Oct; 59(41):4003-4014. PubMed ID: 32954725
[TBL] [Abstract][Full Text] [Related]
11. Quantitative characterization of heparin binding to Tau protein: implication for inducer-mediated Tau filament formation.
Zhu HL; Fernández C; Fan JB; Shewmaker F; Chen J; Minton AP; Liang Y
J Biol Chem; 2010 Feb; 285(6):3592-3599. PubMed ID: 19959468
[TBL] [Abstract][Full Text] [Related]
12. Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice.
Ishihara T; Zhang B; Higuchi M; Yoshiyama Y; Trojanowski JQ; Lee VM
Am J Pathol; 2001 Feb; 158(2):555-62. PubMed ID: 11159192
[TBL] [Abstract][Full Text] [Related]
13. Tau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau.
Yoshida H; Ihara Y
J Neurochem; 1993 Sep; 61(3):1183-6. PubMed ID: 8360683
[TBL] [Abstract][Full Text] [Related]
14. Tau pathology in Alzheimer disease and other tauopathies.
Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
[TBL] [Abstract][Full Text] [Related]
15. Azure C Targets and Modulates Toxic Tau Oligomers.
Lo Cascio F; Kayed R
ACS Chem Neurosci; 2018 Jun; 9(6):1317-1326. PubMed ID: 29378132
[TBL] [Abstract][Full Text] [Related]
16. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
[TBL] [Abstract][Full Text] [Related]
17. Characterization of tau fibrillization in vitro.
Xu S; Brunden KR; Trojanowski JQ; Lee VM
Alzheimers Dement; 2010 Mar; 6(2):110-7. PubMed ID: 20298971
[TBL] [Abstract][Full Text] [Related]
18. Study of the green tea polyphenols catechin-3-gallate (CG) and epicatechin-3-gallate (ECG) as proteasome inhibitors.
Wan SB; Chen D; Dou QP; Chan TH
Bioorg Med Chem; 2004 Jul; 12(13):3521-7. PubMed ID: 15186836
[TBL] [Abstract][Full Text] [Related]
19. Tau proteins and neurofibrillary degeneration.
Goedert M; Spillantini MG; Crowther RA
Brain Pathol; 1991 Jul; 1(4):279-86. PubMed ID: 1669718
[TBL] [Abstract][Full Text] [Related]
20. Disaggregation of tau as a therapeutic approach to tauopathies.
Duff K; Kuret J; Congdon EE
Curr Alzheimer Res; 2010 May; 7(3):235-40. PubMed ID: 20088807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
